Those who consume cannabis and tobacco together face a significantly higher risk of developing a psychotic disorder later on. A study published on May 12, 2026, in Nature Mental Health by Vanderbilt University quantifies this relationship for the first time in clinically identified high-risk individuals. In this group, the risk is nearly three times higher than with abstinence from both substances. The research thus provides a concrete risk figure that has been lacking in previous research on combined use of cannabis and tobacco.
📑 Inhaltsverzeichnis
- The Study: NAPLS Cohort with Two Years of Observation
- The Main Finding: Threefold Risk in Clinical High-Risk Individuals
- Possible Mechanisms: THC Uptake and Lung Irritation
- Implications for German Healthcare and Prevention
- Focus Areas for Future Research
- Frequently Asked Questions
- 💬 Fragen? Frag den Hanf-Buddy!
The Study: NAPLS Cohort with Two Years of Observation
The investigation was led by Heather Ward, Assistant Professor of Psychiatry and Behavioral Sciences and Director of Neuromodulation Research at Vanderbilt Health Center. Her team analyzed data from the North American Prodrome Longitudinal Study, or NAPLS, one of the largest longitudinal studies on early-stage psychotic disorders. The study included 1,012 participants, of whom 734 had a clinically confirmed high risk for later psychotic disorder and 278 healthy control subjects. Over a two-year period, researchers documented which substances participants consumed and in what quantities.
The researchers distinguished five consumption patterns: tobacco only, cannabis only, combined use of both substances, other substances, and abstinence. Combined use was not defined solely as a joint with both substances. Rather, it refers generally to consumption within a time window in which the effects overlap. This broader definition is important because many users do not necessarily mix tobacco and cannabis in the same preparation, but consume both substances in close succession.
The Main Finding: Threefold Risk in Clinical High-Risk Individuals
The key finding concerns a specific group: individuals who combine heavy cannabis use with concurrent light tobacco use and already have a clinically high risk for psychosis. In this constellation, participants developed manifest psychotic disorder nearly three times more frequently during the observation period compared to those without any substance use. This shows that the two substances create not an additive but an interactive risk.
What the study did not find is also noteworthy: regarding short-term symptoms—anxiety, depressed mood, and individual psychotic experiences—there was no clear difference between those with combined use and those using single substances. Only over the multi-year observation period did the threefold risk increase become apparent. This suggests a cumulative effect and makes the study methodologically an important building block for healthcare services research.
Possible Mechanisms: THC Uptake and Lung Irritation
In an interview, Heather Ward points to a pharmacological mechanism: when cannabis is smoked together with tobacco, more THC is absorbed because nicotine affects the airways and alters uptake in lung tissue. This effect has been known for some time and has been confirmed in several studies on the effect of tobacco on cannabis. A higher effective THC dose means a greater risk of psychotic decompensation in genetically or clinically vulnerable individuals.
Adding to this is the chronic irritation of lung mucosa from tobacco smoke, which is already recognized as a risk factor for various mental and somatic illnesses. Other studies, such as a current smoke check comparing tobacco and cannabis, show that tobacco smoke is problematic in practically all combustion-related harmful substance parameters compared to cannabis smoke. In combined use, these exposures accumulate.
Implications for German Healthcare and Prevention
For the German-speaking cannabis industry, addiction support services, and statutory health insurance coverage, the results are relevant for several reasons. In Germany, a considerable portion of consumed cannabis is still mixed with tobacco, more frequently than in the USA or Canada. The study thus provides for the first time a quantitative argument for prevention campaigns that address this cultural standard directly. This is more precise than simply warning abstractly against cannabis in general.
At the same time, the study emphasizes that the threefold risk increase applies to a specific subgroup. Different thresholds apply for the general population without clinical high-risk status. This differentiation is important because evidence-based healthcare services research, such as recent Lancet analyses on cannabis evidence in psychiatry, has for years distinguished itself from one-sided blanket statements. Similarly, the JAMA study on cannabis use in older adults provides an example of how target-group-specific research changes healthcare planning.
Focus Areas for Future Research
Ward announces two research directions that the Vanderbilt team and cooperation partners will pursue next. First, the finding should be replicated in other high-risk cohorts, ideally in Europe, where consumption patterns differ from North America. Second, research should examine whether targeted cessation or reduction of tobacco in vulnerable cannabis users noticeably lowers the risk. Such an intervention study would be an important step from observation to treatment.
Until then, the practical consequence for counseling services and cannabis physicians remains manageable: in patients with a family history of psychosis, with subclinical psychotic experiences, or with other risk indicators, the recommendation is clinically well-founded: do not consume cannabis together with tobacco. This also applies to young users whose brains are still developing and who typically first encounter mixed consumption through tobacco inhalation.
Frequently Asked Questions
Does the threefold risk mean that every combined user will develop psychosis?
No. The threefold risk increase applies to a specific group of clinically identified high-risk individuals—people who already show early signs of psychotic development or have certain risk factors. For the general population, absolute risks are considerably lower, even though combined use is generally considered unfavorable.
Why does combined use have a stronger effect than single use?
Multiple mechanisms come into play. Tobacco alters breathing and leads to higher THC uptake in lung tissue. Additionally, tobacco smoke causes persistent stress to mucous membranes and the cardiovascular system. In vulnerable individuals, these effects accumulate and can increase the likelihood that an existing predisposition becomes manifest illness.
How does this study differ from earlier research?
The NAPLS study is the first to provide a quantitative risk figure specifically for clinically identified high-risk individuals while cleanly separating multiple consumption patterns from one another. Previous studies on cannabis and tobacco have mainly examined general population samples or captured only short-term effects.
What are the implications for cannabis medicine in Germany?
For cannabis patients in medical care, this study is an additional argument for avoiding tobacco during consumption. Vaporization, oral administration, or pure flower preparations without tobacco admixture are already established in healthcare practice. Physicians can use the new study in patient consultations, particularly with young patients with a family history of psychiatric illness.
When can we expect replication of the findings?
Heather Ward’s team and cooperation partners are already working on follow-up studies in additional high-risk cohorts. Reliable replication data could be available within the next two to three years. In parallel, intervention studies are announced that will examine whether tobacco cessation reduces psychosis risk in vulnerable cannabis users.
Konsumierst du Cannabis zusammen mit Tabak oder getrennt?
Source: Vanderbilt Health News, press release of May 12, 2026; Ward et al., Nature Mental Health, May 12, 2026; North American Prodrome Longitudinal Study (NAPLS).
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
